Novo Nordisk Stock: Dominance In The Diabetes Market (NYSE:NVO) | Seeking Alpha
Pharm Exec's 2020 Pipeline Report
Novo Nordisk Boasts Strong Diabetes Presence and Pipeline
Company: Novo Nordisk
Novo Nordisk Explores $800 Million Ziylo Acquisition to Build Insulin Pipeline - Xtalks
Coronary Artery Disease Pipeline Offers Promising New Treatment Options as 23+ Leading Players are Working in the Space | DelveInsight - Netscape Entertainment
R&D pipeline
Novo Nordisk Has Managed The Turnaround (NYSE:NVO) | Seeking Alpha
Novo Nordisk: This Winner Has Risks, Be Aware (NYSE:NVO) | Seeking Alpha
Best in Class Medical/Clinical Science Liaison Customer Insights | Health Industries Research Companies (HIRC)
Now online: 2021 Access to Medicine Index | Access to Medicine Foundation
Anti-obesity drug discovery: advances and challenges | Nature Reviews Drug Discovery
Drug pipeline 1Q20 | Nature Biotechnology
Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus® - MidgardFinance.com
Has the pipe run dry for Novo Nordisk? :: Scrip
Novo Nordisk: The Growth Story Continues With The Latest Results (OTCMKTS:NONOF) | Seeking Alpha
Novo Nordisk 2022: Expanding capabilities – PharmaLive
